Linden Michael, Eich Franz X, Pyrkosch Lena
Research Group Psychosomatic Rehabilitation, Charité, University Hospital Benjamin Franklin, Germany.
Int Clin Psychopharmacol. 2007 May;22(3):175-8. doi: 10.1097/YIC.0b013e3280148c19.
Atypical antipsychotics are often addressed as one class of drugs, although there are marked differences in their pharmacological profiles. It is unknown how this is seen by practitioners and to what extent they differentiate between the various atypical compounds. In a drug utilization study, 472 schizophrenic outpatients who were switched for individual reasons from either olanzapine or risperidone to amisulpride were monitored. Data on patients, illness and treatment as well as on reasons to switch were collected. The reasons to switch from olanzapine to amisulpride were preferably 'weight gain' (72.6% of the physicians), or the 'expectancy of less weight gain with amisulpride' (84.1%) and 'patient request' (60.2%). Specific reasons to switch from risperidone were 'extrapyramidal symptoms' (58.5%), or the 'expectancy of few extrapyramidal symptoms with amisulpride' (82.5%). In conclusion, this study confirms that physicians do not consider 'atypical antipsychotics' as one homogeneous class of drugs but make differences that reflect the specific pharmacological profiles of the respective drugs.
非典型抗精神病药物通常被视为一类药物，尽管它们的药理学特征存在显著差异。目前尚不清楚从业者如何看待这一点，以及他们在多大程度上区分不同的非典型化合物。在一项药物利用研究中，对472名因个人原因从奥氮平或利培酮换用氨磺必利的精神分裂症门诊患者进行了监测。收集了有关患者、疾病和治疗以及换药原因的数据。从奥氮平换用氨磺必利的原因主要是“体重增加”（72.6%的医生选择）、“期望氨磺必利导致体重增加较少”（84.1%）和“患者要求”（60.2%）。从利培酮换用的具体原因是“锥体外系症状”（58.5%），或“期望氨磺必利引起较少的锥体外系症状”（82.5%）。总之，这项研究证实，医生并不认为“非典型抗精神病药物”是一类同质的药物，而是会区分不同药物，这反映了各自药物的特定药理学特征。
